journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/28642335/carcinoid-syndrome-and-costs-of-care-during-the-first-year-after-diagnosis-of-neuroendocrine-tumors-among-elderly-patients
#1
Chan Shen, Yiyi Chu, Daniel M Halperin, Arvind Dasari, Shouhao Zhou, Ying Xu, James C Yao, Ya-Chen Tina Shih
BACKGROUND: Neuroendocrine tumors (NETs) can secrete hormonal peptides that lead to additional symptom burdens. However, it is largely unknown whether and to what extent the additional symptom burdens translate into higher costs of care. This study aimed to examine the cost pattern of elderly NET patients during the first year of diagnosis, taking into account of the carcinoid syndrome status. METHODS: We used Surveillance, Epidemiology, and End Results Medicare data to identify elderly NET patients diagnosed between January 2003 and December 2011...
June 22, 2017: Oncologist
https://www.readbyqxmd.com/read/28642334/alk-fusion-detection-in-circulating-free-dna-finding-an-important-needle-in-the-haystack
#2
Meghan J Mooradian, Justin F Gainor
No abstract text is available yet for this article.
June 22, 2017: Oncologist
https://www.readbyqxmd.com/read/28620092/the-evolution-of-clinical-trials-in-oncology-defining-who-benefits-from-new-drugs-using-innovative-study-designs
#3
EDITORIAL
Richard M Goldberg, Lai Wei, Soledad Fernandez
No abstract text is available yet for this article.
June 15, 2017: Oncologist
https://www.readbyqxmd.com/read/28606973/on-the-receiving-end-of-autonomy-and-law
#4
Hanneke W M van Laarhoven, Lisa J Pijnenburg, Maarten C C M Hulshof
No abstract text is available yet for this article.
June 12, 2017: Oncologist
https://www.readbyqxmd.com/read/28606972/patient-driven-second-opinions-in-oncology-a-systematic-review
#5
Marij A Hillen, Niki M Medendorp, Joost G Daams, Ellen M A Smets
BACKGROUND: Although patient-driven second opinions are increasingly sought in oncology, the desirability of this trend remains unknown. Therefore, this systematic review assesses evidence on the motivation for and frequency of requests for second opinions and examines how they evolve and their consequences for oncological practice. MATERIALS AND METHODS: Relevant databases were sought using the terms "cancer," "second opinion," and "self-initiated." Included were peer-reviewed articles that reported on patient-initiated second opinions within oncology...
June 12, 2017: Oncologist
https://www.readbyqxmd.com/read/28596446/reducing-uncertainty-predictors-of-stopping-chemotherapy-early-and-shortened-survival-time-in-platinum-resistant-refractory-ovarian-cancer-the-gcig-symptom-benefit-study
#6
Felicia T Roncolato, Florence Joly, Rachel O'Connell, Anne Lanceley, Felix Hilpert, Luke Buizen, Aikou Okamoto, Eriko Aotani, Sandro Pignata, Paul Donnellan, Amit Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Florian Heitz, Amanda Feeney, Dominique Berton-Rigaud, Martin R Stockler, Madeleine King, Michael Friedlander
BACKGROUND: Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer (PRROC). This study sought to determine aspects of health-related quality of life and clinicopathological characteristics before starting chemotherapy that were associated with stopping chemotherapy early, shortened survival, and death within 30 days of chemotherapy. MATERIALS AND METHODS: This study enrolled women with PRROC before starting palliative chemotherapy...
June 8, 2017: Oncologist
https://www.readbyqxmd.com/read/28592625/current-clinical-practice-guidelines-for-the-treatment-of-renal-cell-carcinoma-a-systematic-review-and-critical-evaluation
#7
Aristotle Bamias, Bernard Escudier, Cora N Sternberg, Flora Zagouri, Athanasios Dellis, Bob Djavan, Kimon Tzannis, Loukas Kontovinis, Konstantinos Stravodimos, Athanasios Papatsoris, Dionysios Mitropoulos, Charalampos Deliveliotis, Meletios-Athanasios Dimopoulos, Constantine A Constantinides
The landscape of local and systemic therapy of renal cell carcinoma (RCC) is rapidly changing. The increase in the incidental finding of small renal tumors has increased the application of nephron-sparing procedures, while ten novel agents targeting the vascular endothelial growth factor (VEGF) or the mammalian target of rapamycin pathways, or inhibiting the interaction of the programmed death 1 receptor with its ligand, have been approved since 2006 and have dramatically improved the prognosis of metastatic RCC (mRCC)...
June 2017: Oncologist
https://www.readbyqxmd.com/read/28592624/prolonged-pemetrexed-infusion-plus-gemcitabine-in-refractory-metastatic-colorectal-cancer-preclinical-rationale-and-phase-ii-study-results
#8
Alessandro Passardi, Francesca Fanini, Livia Turci, Flavia Foca, Paola Rosetti, Silvia Ruscelli, Andrea Casadei Gardini, Martina Valgiusti, Claudio Dazzi, Maurizio Marangolo
LESSONS LEARNED: Difficulties in translating in vitro results into clinical practice are inevitable.Further efforts to verify the efficacy of alternative schedules of pemetrexed in solid tumors are encouraged. BACKGROUND: We investigated the cytotoxic activity of pemetrexed in combination with several drugs (gemcitabine, carboplatin, vinorelbine, and mitomycin C) using different exposure schedules in three colon cancer cell lines. The best results were obtained with the following schedule: a prolonged pemetrexed exposure followed by a 48-hour wash-out and then gemcitabine...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592623/amani-s-silence
#9
Lea Baider, Lidia Schapira
No abstract text is available yet for this article.
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592622/li-fraumeni-versus-pseudo-li-fraumeni-syndrome-key-insights-for-interpreting-next-generation-sequencing-reports-in-patients-with-suspected-cancer-predisposition-syndromes
#10
Steven Sorscher, Rodwige Desnoyers, Karen Ouyang, Shakti Ramkissoon
No abstract text is available yet for this article.
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592621/bevacizumab-for-metastatic-colorectal-cancer-a-global-cost-effectiveness-analysis
#11
Daniel A Goldstein, Qiushi Chen, Turgay Ayer, Kelvin K W Chan, Kiran Virik, Ariel Hammerman, Baruch Brenner, Christopher R Flowers, Peter S Hall
BACKGROUND: In the U.S., the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality-adjusted life years (QALYs) at an incremental cost-effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value for money may be different in other countries. Our objective was to establish the cost-effectiveness of bevacizumab in mCRC in the U.S., U.K., Canada, Australia, and Israel. METHODS: We performed the analysis using a previously established Markov model for mCRC...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592620/phase-ii-study-of-first-line-trebananib-plus-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma
#12
Ghassan K Abou-Alfa, Jean-Frederic Blanc, Steven Miles, Tom Ganten, Jörg Trojan, Jonathan Cebon, Andre K Liem, Lara Lipton, Charu Gupta, Benjamin Wu, Michael Bass, Ellen Hollywood, Jennifer Ma, Margaret Bradley, Jason Litten, Leonard B Saltz
LESSONS LEARNED: Trebananib leveraging anti-angiogenic mechanism that is distinct from the classic sorafenib anti-vascular endothelial growth factor inhibition did not demonstrate improved progression-free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC).In support of previously reported high Ang-2 levels' association with poor outcome in HCC for patients, trebananib treatment with lower baseline Ang-2 at study entry was associated with improved overall survival to 22 months and may suggest future studies to be performed within the context of low baseline Ang-2...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592619/incorporating-tumor-characteristics-to-the-american-joint-committee-on-cancer-breast-cancer-staging-system
#13
Mariana Chavez-MacGregor, Elizabeth A Mittendorf, Christina A Clarke, Daphne Y Lichtensztajn, Kelly K Hunt, Sharon H Giordano
BACKGROUND: The American Joint Committee on Cancer (AJCC) breast cancer staging system provides important prognostic information. The recently published eighth edition incorporates biological markers and recommends the use of a complex "prognostic stage." In this study, we assessed the relationship between stage, breast cancer subtype, grade, and outcome in a large population-based cohort, and evaluate a risk score system incorporating tumor characteristic to the AJCC anatomic staging system...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592618/efficacy-and-safety-of-pertuzumab-and-trastuzumab-administered-in-a-single-infusion-bag-followed-by-vinorelbine-velvet-cohort-2-final-results
#14
Michael Andersson, José M López-Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia, Edith A Perez
BACKGROUND: VELVET Cohort 1 demonstrated the applicability of pertuzumab, trastuzumab, and vinorelbine as an alternative first-line treatment regimen for patients with HER2-positive locally advanced or metastatic breast cancer (MBC) who cannot receive docetaxel. Co-infusion of pertuzumab and trastuzumab may reduce clinic time and medical resource utilization. We report results from Cohort 2, in which pertuzumab and trastuzumab were co-infused, followed by vinorelbine. PATIENTS AND METHODS: During cycle 1, patients with HER2-positive locally advanced or MBC received loading doses of pertuzumab (840 mg) and trastuzumab (8 mg/kg) on consecutive days, followed by vinorelbine (25 mg/m(2)) on days two and nine...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592617/the-patients-we-have-to-see
#15
Kelly E Irwin
No abstract text is available yet for this article.
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592616/multicenter-phase-ii-study-of-panitumumab-in-platinum-pretreated-advanced-head-and-neck-squamous-cell-cancer
#16
Marco Siano, Francesca Molinari, Vittoria Martin, Nicolas Mach, Martin Früh, Stefania Freguia, Irene Corradino, Michele Ghielmini, Milo Frattini, Vittoria Espeli
LESSONS LEARNED: Panitumumab shows activity in terms of disease control rate and preventing disease progression but not for tumor shrinkage in head and neck squamous cell cancer for second-line treatment. Epidermal growth factor receptor (EGFR) copy number gain, a property of tumor cells that theoretically could identify patients more likely to experience disease response, was common among patients having disease control.Our trial, given the lower toxicity with an every-2-week schedule, provides guidance for future trials, for example, in combinations of immune therapies and anti-EGFR-antibodies...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28592615/a-phase-ib-dose-escalation-study-of-the-safety-tolerability-and-pharmacokinetics-of-cobimetinib-and-duligotuzumab-in-patients-with-previously-treated-locally-advanced-or-metastatic-cancers-with-mutant-kras
#17
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, Andrew H Ko, Andres Cervantes, Patricia LoRusso, David E Gerber, J Paul Eder, S Gail Eckhardt, Amy V Kapp, Amy Tsuhako, Bruce McCall, Andrea Pirzkall, Anne Uyei, Josep Tabernero
LESSONS LEARNED: Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents.The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested. BACKGROUND: KRAS-mutant tumors possess abnormal mitogen-activated protein kinases (MAPK) pathway signaling, leading to dysregulated cell proliferation. Cobimetinib blocks MAPK signaling...
June 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28576859/regarding-oncology-drug-approvals-evaluating-endpoints-and-evidence-in-an-era-of-breakthrough-therapies
#18
EDITORIAL
Bruce A Chabner
No abstract text is available yet for this article.
June 2, 2017: Oncologist
https://www.readbyqxmd.com/read/28576857/braf-mutations-as-predictive-biomarker-for-response-to-anti-egfr-monoclonal-antibodies
#19
Emilie M J van Brummelen, Anthonius de Boer, Jos H Beijnen, Jan H M Schellens
Recently, the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) recommended that patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer could be treated with anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab only in absence of Rat-Sarcoma (RAS) mutations. In addition to the previously established biomarker Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, cumulative evidence also shows that patients whose tumors harbor KRAS exons 3 or 4 and neuroblastoma rat-sarcoma viral oncogene homolog (NRAS) exons 2, 3, and 4 mutations are found unlikely to benefit from anti-EGFR treatment...
June 2, 2017: Oncologist
https://www.readbyqxmd.com/read/28576856/oncology-drug-approvals-evaluating-endpoints-and-evidence-in-an-era-of-breakthrough-therapies
#20
Gideon M Blumenthal, Paul G Kluetz, Julie Schneider, Kirsten B Goldberg, Amy E McKee, Richard Pazdur
No abstract text is available yet for this article.
June 2, 2017: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"